Dialysis center valuation starts with EBITDA—earnings before interest, taxes, depreciation, and amortization. For a dialysis center operating a 25-bed unit with 18 average patients at 72 treatments annually per patient (12 monthly treatments), generating approximately $1.5M annual revenue at 28% EBITDA margins, your EBITDA is $420K. Current market range for dialysis centers is 6.0x–12.0x EBITDA, translating to valuations between $2.52M and $5.04M. However, the multiple your center commands depends entirely on six quantifiable value drivers.

Start by calculating EBITDA accurately. Use your last 3 years of tax returns and internal P&Ls, adjusting for one-time items (major equipment replacement, settlement costs, facility repairs). Most dialysis centers run 25–32% EBITDA margins. If you're running <20%, investigate labor cost, reimbursement pressure, or operational inefficiency. Many center operators don't accurately allocate nursing labor, support staff, or facility overhead.

Second, analyze your patient census and trend. This is the single strongest driver of valuation. Document your monthly patient census for the past 3 years. Calculate your average monthly census, trend (growth or decline rate), and volatility (standard deviation). A stable center with 18–20 average patients and <1% monthly volatility is strong. A declining center losing 1–2 patients monthly signals referral network weakness or quality issues. Calculate your projected census with current trends. If census is declining, valuation faces discounts of 0.5x–1.0x EBITDA.

Third, assess treatment volume and station utilization. Document your station count, days of operation weekly (typically 5–5.5 days for in-center hemodialysis), treatment sessions daily, and average patients per station. Calculate monthly treatment sessions: (average patients × 12 monthly treatments). Calculate station utilization: (monthly treatments ÷ theoretical maximum capacity) × 100. If you're operating 25 stations, 5 days weekly, with 12 treatment slots daily per station (4-hour sessions), you have 300 weekly slots (1,300 monthly). If you're running 975 monthly treatments, you're at 75% utilization—acceptable but room for growth. Aim for 85–90% utilization.

Fourth, analyze your payer mix. Document your patient population by payer: count and revenue percentage for commercial insurance, Medicare, and Medicaid. Calculate your weighted-average reimbursement per treatment. If you're running 50%+ commercial payer mix at $240+ per treatment, your reimbursement is strong. If you're 70%+ Medicare-only at $135 per treatment, your reimbursement is pressured. Payer mix is 20–25% of valuation impact—centers with strong commercial mix command premium valuations.

Fifth, assess regulatory compliance and quality metrics. Document your most recent CMS survey: survey date, deficiencies (if any), remediation status, and current certification status. If you have clean surveys, that's strong. Any deficiencies reduce valuation by 0.5x–1.0x EBITDA. Document your current CMS Star Rating and the clinical metrics driving it: mortality rate (target <10%), infection rate (target <20 per 100 patient-months), hospitalization rate (target <1.0 per patient-year), and laboratory parameter achievement rates. Centers achieving 5-star ratings command 1.0x–1.5x EBITDA premium.

Sixth, evaluate your nephrologist relationships. Document your medical director: nephrologist, full-time vs. part-time, tenure. Identify your top 10 referring nephrologists and estimated patient referrals per nephrologist annually. If you have 5–8 active referring nephrologists providing steady referrals, your referral network is diversified. If you're dependent on 1–2 nephrologists, you have concentration risk. Medical director engagement is critical—if your medical director is actively involved in clinical protocols and patient outcomes, that's valuable. Inactive medical directors signal operational risk.

Once quantified, map drivers to multiples. A center with: (1) stable census at 85%+ utilization, (2) 30%+ commercial payer mix, (3) clean CMS surveys, (4) 5-star Star Rating (<9% mortality, <18% infections), and (5) strong medical director and nephrologist network, commands 9.0x–12.0x EBITDA. A center with declining census, 70%+ Medicare-only payer mix, regulatory deficiencies, and weak medical director engagement sees 6.0x–7.5x EBITDA.

Calculate weighted drivers: census stability (30%), utilization (15%), payer mix (20%), regulatory (20%), quality metrics (10%), nephrologist relationships (5%). Score each 1–10. If weighted average is 8.5+, aim for 9.0x–12.0x EBITDA; if 6.5–8.0, target 7.5x–9.0x; if <6.5, expect 6.0x–7.5x.

Understand buyer types. Strategic buyers (large dialysis networks like DaVita, Fresenius, Renal Advantage, private equity consolidators) pay 8.0x–12.0x EBITDA because they add operational scale and margin. PE buyers pay 7.0x–10.0x EBITDA. Local buyers (physicians, hospitals) pay 6.5x–9.0x EBITDA. Each buyer values drivers differently—networks value census stability and payer mix; PE values EBITDA and operational improvement; local buyers value relationships and community positioning.

Final validation: revenue multiples. A center generating $1.5M revenue with census of 18 patients at 72 treatments annually, valued at $4.2M (10x EBITDA at 28% margins), is 2.8x revenue. Dialysis centers typically trade 2.0x–3.5x revenue depending on census stability and payer mix; 2.8x is reasonable for a stable center with balanced payer mix.